Anthera Pharmaceuticals (ANTH) Stock Rating Upgraded by Zacks Investment Research

Anthera Pharmaceuticals (NASDAQ:ANTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage presently has a $1.75 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 8.02% from the stock’s previous close.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

Separately, ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st.

Anthera Pharmaceuticals (NASDAQ ANTH) traded up $0.03 during trading on Tuesday, reaching $1.62. 120,966 shares of the company’s stock traded hands, compared to its average volume of 681,916. The firm has a market capitalization of $22.44, a price-to-earnings ratio of -0.30 and a beta of 2.66. Anthera Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $6.24.

A hedge fund recently raised its stake in Anthera Pharmaceuticals stock. Wedbush Securities Inc. boosted its position in shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 75.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 73,764 shares of the biopharmaceutical company’s stock after purchasing an additional 31,800 shares during the period. Wedbush Securities Inc. owned 0.68% of Anthera Pharmaceuticals worth $106,000 at the end of the most recent reporting period. 16.21% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Anthera Pharmaceuticals (ANTH) Stock Rating Upgraded by Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/13/anthera-pharmaceuticals-anth-stock-rating-upgraded-by-zacks-investment-research.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply